Oral Drug Candidate Showed Promise for Retinal Health
A new pill for non-proliferative diabetic retinopathy may one day replace invasive eye injections.
Updated on Sept. 23, 2026 in Diabetes
Live Poll
Would you prefer oral medication over eye injections for treating chronic retinal conditions?
An academic paper published in Science Translational Medicine has detailed pre-clinical and Phase 1b clinical data for an oral drug candidate, danegaptide. The treatment is being developed for people with non-proliferative diabetic retinopathy (NPDR).
Why it matters
Current NPDR treatments rely on invasive intravitreal injections that can be burdensome for patients, making the development of an oral alternative a significant shift in potential care. If proven effective in later trials, this approach could improve patient compliance and access to early treatment.
A recently published analysis synthesized pre-clinical and Phase 1b trial data for danegaptide. While early results appear promising, the findings remain preliminary pending larger Phase II studies.
The players
Breye Therapeutics
A Copenhagen-based developer focused on novel therapies for retinal conditions including diabetic retinopathy.
The details
Danegaptide functions as an oral small molecule designed to stabilize retinal vasculature and protect the inner blood-retina barrier. By dampening VEGF-associated activity, the drug aims to prevent the capillary breakdown that characterizes diabetic retinopathy. Unlike current standards of care that require direct eye injections, this pill-based delivery system is intended to reduce the burden of treatment for the 130 million people currently living with this condition.
Timeline
September 23, 2026: Academic paper on danegaptide published in Science Translational Medicine.
2027: Planned start of Phase II clinical trial.
Health Landscape
For millions of individuals with diabetic retinopathy, treatment has long been defined by invasive intravitreal injections. This development signals a potential evolution in the research pipeline toward less burdensome, systemic approaches to managing vascular eye health.
Those currently managing diabetic retinopathy should continue their prescribed treatment plans, as this medication is still in early-stage research. Discuss any questions about new treatment options or long-term management with your ophthalmologist or endocrinologist.
The takeaway
Danegaptide represents a shift toward oral treatments for retinal disease, though it is not yet available for patient use. Patients should maintain communication with their medical team regarding established guidelines for managing retinal health and screening for diabetes-related complications.
What happens next
Breye Therapeutics intends to initiate a Phase II clinical trial for danegaptide in 2027.
Further reading
Explore the latest clinical developments and management strategies in our Diabetes section.
More information
For more information on the company's research pipeline, visit the Breye Therapeutics corporate website.
Live Poll
Would you prefer oral medication over eye injections for treating chronic retinal conditions?
